MCM
PTGX icon

Moore Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Moore Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,580
Closed -$624K – 577
2023
Q2 		$624K Buy
+22,580
New +$565K 0.01% 331

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moore Capital Management's PTGX Position: Q3 2023 in Review

Moore Capital Management sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 22,580 shares — an estimated $624K sold.

Moore Capital Management first reported a position in PTGX in Q2 2023 and held it in 1 quarter. The position peaked at $624K in Q2 2023. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

  • Moore Capital Management reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Moore Capital Management sold 22,580 Protagonist Therapeutics shares in Q3 2023, an estimated $624K.
  • Moore Capital Management first reported a position in Protagonist Therapeutics in Q2 2023 and held it in 1 quarter.
  • Moore Capital Management's Protagonist Therapeutics position peaked at $624K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.